← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Baruch S. Blumberg Institute
Doylestown, PA
$34,666,661
Total funding
19
Grants
Funding over time
peak $9M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,361,990 · 14
DOD$6,304,671 · 5
By mechanism
N01$12,480,276 · 1
R01$11,848,461 · 5
—$6,304,671 · 5
R21$2,007,258 · 5
U01$1,112,955 · 1
R56$643,042 · 1
Investigators at Baruch S. Blumberg Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF AN ANTIVIRAL FOR YELLOW FEVER VIRUS INFECTION$5,493,876
N01 · FY2023 · AI
Development of an Antiviral to Combat Viral Infections$4,020,000
N01 · FY2024 · AI
Development of an Antiviral for Yellow Fever Virus Infection$2,966,400
N01 · FY2024 · AI
MECHANISM OF CPAM-INDUCED HBV CORE PROTEIN DEGRADATION AND THERAPEUTIC IMPLICATION$1,742,434
· FY2021 · Defense Health Agency
MOLECULAR MECHANISM OF THE DUAL EFFECTS OF CAPSID ASSEMBLY EFFECTORS ON HBV CAPSID ASSEMBLY AND DISASSEMBLY$1,664,746
· FY2017 · Department of the Army
NOVEL MECHANISMS GOVERNING HUMAN BREAST CANCER CHROMOSOMAL INSTABILITY$1,191,000
· FY2024 · Defense Health Agency
NOVEL MECHANISMS GOVERNING HUMAN BREAST CANCER CHROMOSOMAL INSTABILITY$1,111,051
· FY2018 · Department of the Army
A small molecule for management of filovirus hemorrhagic fevers$980,944
R01 · FY2017 · AI
A small molecule for management of filovirus hemorrhagic fevers$950,337
R01 · FY2015 · AI
A small molecule for management of filovirus hemorrhagic fevers$879,526
R01 · FY2016 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever$723,640
R01 · FY2018 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever$723,640
R01 · FY2019 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever$716,197
R01 · FY2020 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever$692,067
R01 · FY2021 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever$680,797
R01 · FY2022 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$669,728
R01 · FY2015 · AI
DEVELOPMENT OF INHIBITORS OF RAD52 PROTEIN AGAINST BRCA-DEFICIENT BREAST CANCER$595,440
· FY2020 · Defense Health Agency
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$578,621
R01 · FY2016 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$537,218
R01 · FY2018 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$511,927
R01 · FY2017 · AI